The American Kratom Association (AKA) has welcomed new American Medical Association (AMA) policy targeting highly concentrated 7‑hydroxymitragynine (7‑OH) products, while warning that imprecise language risks misleading the public about traditional kratom.
In a press release published via Yahoo Finance, the AKA applauded the AMA for calling out chemically manipulated 7‑OH opioids and backing tighter controls on their sale and marketing, especially around minors. However, AKA policy fellow Mac Haddow argued that repeatedly labeling these synthetically boosted 7‑OH products as “kratom” obscures the crucial distinction between natural leaf and laboratory-altered opioids.
Natural kratom leaf is dominated by mitragynine, with 7‑OH only in trace amounts, while new products “reverse” that profile through chemical conversion. Citing an FDA‑oversighted human dose‑finding study in which adults tolerated up to 12 grams of kratom leaf without serious adverse events, the AKA urged policymakers to regulate manipulated 7‑OH opioids separately from traditional kratom.
